Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Trial details
- Registry ID
- NCT00589875
- Phase
- Phase 2
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875 | CADL | Phase 2 | Completed | 2015-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |